We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need. Our initial program is gene therapy for early stage bladder cancer. Inodiftagene vixteplasmid (formerly BC-819) is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC). Inodiftagene has been tested in six clinical trials to date, three of which are in NMIBC. The pivotal development program comprises two registrational trials in NMIBC. The first of these, the Codex Trial, opened in December of 2018 and is recruiting patients now (link to ClinicalTrials.gov). We are located in Cambridge, MA, and in Jerusalem, and are publicly traded on the Nasdaq (NASDAQ: ANCN). Our R&D activities build upon the discovery by Professor Avraham Hochberg, of the Hebrew University of Jerusalem, of the human H19 gene. It has been shown that the gene is expressed in over forty different forms of cancer, including especially bladder cancer, while being quiescent in most normal adult tissues. H19-based therapy is designed to be a highly selective method of killing cancer cells that spares normal bladder tissue. Source
No articles found.
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal a...
Immunomedics is a clinical-stage biopharmaceuti...
Sanofi is dedicated to supporting people through their health challenges. We are a...
Sanofi is dedicated to supporting people throug...
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug p...
Enlivex is a clinical stage immunotherapy compa...
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
Cortexyme is a biopharmaceutical company developing therapeutics based on data sup...
Cortexyme is a biopharmaceutical company develo...
Gamida Cell is a clinical-stage biopharmaceutical company committed to developing ...
Gamida Cell is a clinical-stage biopharmaceutic...
VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biopharm...
VBL Therapeutics is a publicly traded (NASDAQ: ...
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-bas...
Genomic Health, Inc. (NASDAQ: GHDX) is the worl...
Join the National Investor Network and get the latest information with your interests in mind.